99 results about "Synovial membrane" patented technology

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.

A weft yarn for an artificial ligament (1), a weft yarn preparation method, and an artificial ligament (1). The artificial ligament (1) is of a round rod structure; a first woven part (102), an in-joint free filament part (103), and a second woven part (104) which are sequentially connected are formed in the round rod structure in the axial direction thereof; the in-joint free filament part (103) comprises a plurality of weft yarns (201), and the weft yarns (201) extend in the axial direction of the round rod structure; and each weft yarn (201) has a fineness of 1000 D-3000 D / 1-100 F, and a mechanical strength of 75-300 N. By increasing the mechanical strength of a single yarn formed in the in-joint free filament part (103) of the artificial ligament (1), the number of yarns in the in-joint free filament part (103) is decreased. The present invention can eliminate a knee joint synovial membrane inflammatory response caused by chippings of the artificial ligament (1) in the reconstruction process of the artificial ligament (1), reduce the degree of contact adhesion between the in-joint free filament part (103) and the tissue, reduce the probability of adhesion, and solve the clinical problems of the inflammatory response and the prolonged surgery time which are caused by difficult removal due to adhesion of the free filaments and the tissue in the revision surgery.

The invention relates to application of a miR-155-5p inhibitor delivered by an exosome of a targeted synovitis macrophage to treatment of osteoarthritis, and belongs to the technical field of biological medicines. According to the scheme, the exosome drug delivery system for targeting the synovial inflammatory macrophages in the osteoarthritis, which contains the miR-155-5p inhibitor, is prepared through a genetic engineering technology, so that the exosome derived from stem cells is targeted to inflammatory synovial tissues, and damaged cartilage tissues are repaired and inflammation is resisted based on the stem cell exosome; compared with the prior art, the application has the advantages that the combined action of inhibiting the osteoarthritis injury and inhibiting the miR-155-5p so as to resist synovitis is realized, the osteoarthritis injury repair can be better applicable, a new scheme for treating the osteoarthritis is provided, a support is provided for clinical transformation, and the application value is extremely high.

The invention belongs to the field of biomedicine, and provides application of LDHA as a treatment target of aging-related osteoarthritis. In-vitro cell experiments and animal in-vivo experiments prove that the LDHA inhibitor can inhibit OA progress caused by aging, and targeted inhibition of LDHA in synovial fibroblasts can provide a brand-new treatment strategy for treatment of aging-related osteoarthritis.

The application provides a kind of load exosome composite hydrogel and preparation method thereof, belong to biomaterial and drug delivery technical field;Its preparation method includes: modified chitosan;Modified hyaluronic acid;Preparation of biphasic calcium phosphate nanoparticles;Preparation of composite hydrogel.The application is through nucleophilic ring-opening reaction of 1,2-epoxy butane and the hydroxyl group of chitosan, form hydroxybutyl ether bond, give hydroxybutyl chitosan temperature sensitive characteristics, then, again, after activation 3,4-dihydroxyphenylalanine is condensed with hydroxybutyl chitosan, form amide bond, to graft 3,4-dihydroxyphenylalanine on hydroxybutyl chitosan, after modification of chitosan, 3,4-dihydroxyphenylalanine can form strong adhesion interface with cartilage, synovial membrane and other tissues through hydrogen bond, pi-pi stacking and metal coordination, thereby effectively prolonging the residence time of hydrogel in joint.

The invention belongs to the field of biological medicine, and discloses a chicoric acid (CA)-loaded tetrahedral framework nucleic acid (tFNA) nano preparation for treating acute gouty arthritis. According to the preparation, tFNA formed by self-assembly is taken as a carrier, and a natural active ingredient CA is loaded to form a CA-tFNA compound. The compound overcomes the defects that CA is poor in water solubility and low in bioavailability, and existing drugs are weak in targeting and large in side effect. Through the targeted delivery and synergistic effect of tFNA, the preparation can be effectively enriched in inflammatory joints, significantly inhibit NF-kappa B signal pathways, and down-regulate the expression of key proinflammatory factors such as TNF-alpha and IL-1beta, so that joint swelling and synovial tissue damage are relieved, and repair is promoted. Experiments show that the traditional Chinese medicine composition is remarkable in curative effect and good in safety, and a novel efficient treatment strategy is provided for acute gouty arthritis.

The present invention relates to a composition and method for treating rheumatoid arthritis, comprising interleukins (ILs), including IL-1β, stimulated human umbilical cord mesenchymal stem cells (hUCMSCs). The IL stimulated hUCMSCs of the present invention may induce the apoptosis of fibroblast-like synoviocytes rheumatoid arthritis (HFLS-RA) cells. IL stimulated hUCMSCs are useful to alleviate RA symptoms, such as inflammation, swelling and cartilage erosion, and exhibit therapeutic effects on rheumatoid arthritis.

The invention discloses an application of TRBC2 in diagnosis of gout. According to the application, a recognized moving meniscus tearing patient (equivalent to a completely healthy synovial tissue) without gout medical history is taken as a contrast, single cell transcriptome analysis is carried out on the basis of a clinical biological sample, and a marker TRBC2 of a T cell subset is found to have significant difference in gout patients; a Raman spectrum technology is further adopted to find that the TRBC2 protein is specifically and highly expressed in synovial tissues of gouty arthritis patients and has relatively high diagnosis efficiency, and the TRBC2 is relatively high in clinical value and wide in application prospect when being used as a marker for diagnosing gout.

The drainage pipeline structure comprises a drainage blind ditch, a communication part and a drainage part, the drainage blind ditch is arranged between a rock mass surface and a vertical shaft lining, and the drainage blind ditch is used for collecting leakage water of a rock mass; the communicating part comprises a three-way connecting piece, a pre-buried drainage pipe and a filling material, the pre-buried drainage pipe extends in the thickness direction of the vertical shaft lining and penetrates through the vertical shaft lining, the three-way connecting piece communicates with the drainage blind ditch and the pre-buried drainage pipe, and the filling material is arranged on the side, away from the three-way connecting piece, of the pre-buried drainage pipe and detachably connected with the pre-buried drainage pipe; the end parts of the embedded drainage pipe and the filling material do not exceed the inner wall surface of the vertical shaft lining; and the drainage part is configured to be connected with the pre-embedded drainage pipe after the filling material is detached, and the drainage part is used for draining leakage water. The drainage pipeline structure for the slip form construction does not affect normal construction of the slip form, and can ensure safe drainage of mountain leakage water after the slip form construction is completed.

The invention provides an EP300 detection preparation and application of EP300 in a product for treating rheumatoid arthritis, and relates to the technical field of biological medicines. The rheumatoid arthritis symptom is relieved by inhibiting EP300 gene expression, after EP300 is knocked down in human THP-1-derived macrophages, H3K18 lactylation expression is reduced, and after EP300 is knocked down in human THP-1-derived macrophages, EP300 and human synovial cells are co-cultured, so that the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, and the human THP-1-derived macrophages are obtained. Through the crosstalk effect between human THP-1-derived macrophages and human synovial cells, the expression of inflammatory markers MMP3 and Fibronectin in the synovial cells can be remarkably inhibited, compared with a model group, the proliferation capacity of the synovial cells is weakened, a potential treatment target is provided for treating rheumatoid arthritis, and the application has the advantages that the application is easy to popularize and use, and the application has a wide application prospect. The pathogenesis of rheumatoid arthritis is perfected, and hope is brought to research and development of novel biomarkers for early diagnosis, targeted therapy and prognosis evaluation of rheumatoid arthritis.

The invention discloses a construction method of a synovial sarcoma tumor ball vascular induction model, the model and application of the synovial sarcoma tumor ball vascular induction model. The construction method of the synovial sarcoma tumor sphere vascular induction model comprises the following steps: S1, suspension culture of synovial sarcoma organs; and S2, constructing a synovial sarcoma tumor ball vascular induction model based on the culture chip. When the synovial sarcoma organ is cultured, the synovial sarcoma primary tissue is cultured in a suspension culture mode, and the method not only can improve the proliferation speed of the synovial sarcoma organ, the cell growth state is better, the activity is higher, but also has the advantage of simplicity in operation. Besides, the synovial sarcoma tumor sphere vascular induction model is constructed based on the culture chip, and the model can simulate tumor microenvironment more truly, has tumor-related fibroblast and vascular components, and provides more clinical drug sensitivity test results.

The invention provides a muscle-bone injury area identification method and system, and relates to the technical field of muscle-bone image injury identification. The method comprises the following steps: acquiring a two-dimensional gray-scale ultrasonic image of a target muscle-bone injury area, and positioning a synovial tissue area from the two-dimensional gray-scale ultrasonic image; extracting target feature information from the synovial tissue region; and determining the inflammation activity degree of the synovial tissue according to the target feature information. According to the method, Doppler blood flow signals are completely bypassed, the rheumatism inflammation activity degree is evaluated only through rich information contained in the two-dimensional gray-scale ultrasonic image, and therefore interference of probe pressure artifacts is thoroughly avoided.

The invention discloses a pathological microenvironment self-driven precise targeting nano-robot as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing an MOF carrier; (2) preparing MOF-coated ISLamp; a CORM-401 compound, and an organic solvent; (3) preparing apoptotic cell membranes; (4) preparing an FH peptide modified apoptosis cell membrane: coupling the FH peptide with a synthetic sequence of FHKHKSPALSPV with DSPE-PEG-NHS, then mixing with apM, carrying out ultrasonic treatment, and carrying out centrifugal purification to obtain FM; (5) preparing a nano robot: MOF (at) ISLamp; the CORM-401 and the FM membrane protein are mixed, asymmetrically wrapped, extruded to pass through a membrane, and centrifuged to obtain the nano-robot. According to the designed self-driven nano-robot integrating the triple functions of self-driving, precise targeting and collaborative treatment, CORM-401-ROS reaction is used for providing active power to break through a synovial membrane barrier, targeted enrichment of core pathological cells is achieved through an engineered cell membrane, the mitochondrial function is synergistically repaired by means of ISL and CO, OA pathological circulation is blocked, and the targeted enrichment of the core pathological cells is achieved. A brand new technical scheme is provided for treatment of osteoarthritis from symptomatic remission to pathological reversion.

The application discloses a kind of nanoclusters with golgi targeting and its preparation method and application, the nanocluster is zinc sulfide nanocluster, the surface of the zinc sulfide nanocluster is coupled with targeting ligand, the targeting ligand can actively target RA synovial activated macrophage, and can target golgi subcellular organelle, the nanocluster can release H2S gas in inflammatory weak acid microenvironment.The application can realize "inflammatory joint enrichment-> macrophage active uptake-> lysosome escape-> golgi deep anchoring" multi-level precise delivery, release H2S gas in inflammatory weak acid microenvironment, fundamentally reshape intracellular Ca 2+ Steady state, relieve endoplasmic reticulum, golgi and mitochondria triple stress, block inflammatory signal pathway, realize the efficient, safe treatment of RA.

The application provides a pharmaceutical composition for treating rheumatoid arthritis, which is composed of paeoniflorin, glycyrrhizin, glycyrrhizic acid and glycyrrhetic acid in a weight ratio of (4.5-7.5):(0.4-1.8):(1.8-4.3):(22-40). The pharmaceutical composition can significantly inhibit the proliferation of fibroblast-like synoviocytes, reduce the secretion of inflammation-related factors (TNF-alpha, IL-1beta, IL-6 and COX-2), regulate the expression of TNF-alpha / NF-kappaB signal pathway-related proteins, and has a significant curative effect on rheumatoid arthritis.

The application discloses a pathological microenvironment self-driven precise targeted nanorobot and a preparation method and application thereof, and is prepared according to the following steps: (1) preparing a MOF carrier; (2) preparing a MOF@ISL&CORM-401 compound; (3) preparing an apoptotic cell membrane; (4) preparing an FH peptide modified apoptotic cell membrane: coupling FH peptide with a sequence of FHKHKSPALSPV and DSPE-PEG-NHS, mixing with apM under ultrasonic, centrifugal purification, and obtaining FM; (5) preparing a nanorobot: mixing the MOF@ISL&CORM-401 and the membrane protein of FM, asymmetrically wrapping, extruding through the membrane, and centrifugal to obtain the nanorobot. The self-driven nanorobot with the triple functions of self-driving, precise targeting and synergistic treatment is designed, the CORM-401-ROS reaction is utilized to provide active power to break through the synovial membrane barrier, the engineered cell membrane is utilized to realize the targeted enrichment of core pathological cells, the ISL and CO are utilized to repair the mitochondrial function, and the OA pathological cycle is blocked, so that a novel technical scheme is provided for the treatment of osteoarthritis from the symptomatic relief to the pathological reversal.

The invention provides a synovial membrane stem cell subgroup with spontaneous chondrogenic differentiation capability and a separation method, an identification method and application thereof, the cell surface of the synovial membrane stem cell subgroup with spontaneous chondrogenic differentiation capability simultaneously expresses CDH13 and CD90, and the expression of NOTCH3 is deleted or the expression level of NOTCH3 is lower than a preset threshold value. The synovial stem cell subgroup with the spontaneous chondrogenic differentiation capacity is obtained and can be spontaneously differentiated into chondrocytes under the basic culture condition without adding growth factors, and better seed cells are provided for articular cartilage injury repair; the problems of inaccurate cartilage regeneration seed cell source, tedious induction steps and the like in the prior art are solved.

This invention discloses a novel application of the RNA-binding protein HNRNPA1 in regulating copper death in synovial fibroblasts of rheumatoid arthritis (RA-FLS). Overexpression of HNRNPA1 recognizes and binds to the m6A modification site of SLC3A2 mRNA, enhancing its transcript stability, restoring the expression of SLC3A2 and copper death-related proteins, reducing MDA levels, increasing copper ion concentration and the activity of antioxidant enzymes SOD and POD, thereby repairing mitochondrial ultrastructural damage, inhibiting abnormal cell proliferation, and inducing apoptosis. Reversal experiments confirmed that knocking down SLC3A2 reverses the above effects, indicating that SLC3A2 is a core downstream target of HNRNPA1-mediated copper death. This invention reveals for the first time the decisive role of the HNRNPA1-SLC3A2-copper death axis in the pathological phenotype of RA-FLS, providing a new target for molecular intervention in rheumatoid arthritis.

The application discloses a multi-component synovitis treatment composition based on repairing cartilage tissue and application thereof, and relates to the technical field of biological medicine, and the composition is composed of glucosamine hydrochloride, chondroitin sulfate, dimethyl sulfone and graded molecular weight sodium hyaluronate; the application precisely compounding the graded molecular weight sodium hyaluronate with the glucosamine hydrochloride, the chondroitin sulfate and the dimethyl sulfone according to weight parts, constructs a gradient slow-release and target delivery system of synovitis lesions, specifically inhibits the activity of hyaluronidase in the inflammatory joint cavity by using the dimethyl sulfone, greatly reduces the degradation of the sodium hyaluronate, prolongs the residence time of the active ingredients at the lesion site, realizes immediate analgesia and relieves joint stiffness by quickly forming a lubricating protective film by the high molecular weight sodium hyaluronate, the medium and low molecular weight sodium hyaluronate penetrates the synovial membrane barrier and carries the cartilage repair components to enrich in the cartilage defect area, and the synergistic effect of the components is realized.

The invention provides a benzylimidazole glutamine cyclase inhibitor as well as a preparation method and application thereof, and belongs to the field of medical chemistry. The compound as shown in the formula I is prepared, the compound has good inhibitory activity on glutamine cyclase, and the half inhibitory concentration of most compounds reaches the nanomole level; the compound has a wide application prospect in preparation of drugs for treating Alzheimer's disease, depression, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, tumor, synovial membrane disease, gout, acute / chronic enteritis, rheumatoid arthritis or inflammatory diseases, and lays a material basis for research and development of related drugs.

The present invention provides the use of NAMPT inhibitors in the manufacture of medicaments for preventing and / or treating pigmented villonodular synovitis (PVNS), and belongs to the field of medicine. In the present invention, based on the PVNS-PDX mouse model, it is found that NAMPT inhibitor FK866 exhibits significant therapeutic effects on PVNS, such as improving clinical symptoms related to the disease and inhibiting the proliferation of PVNS grafts. It is discovered that FK866 can target the NAMPT-ITGA5-JUND signaling axis, alleviate endothelial cell damage and vascular permeability, reduce synovial inflammation, decrease the volume of synovial tumor grafts, mitigate hemorrhagic lesions of PVNS, and hinder tumor progression. Therefore, NAMPT inhibitors have broad application prospects in the manufacture of medicaments for preventing and / or treating PVNS.

The application discloses application of TRBC2 in diagnosis of gout. In the application, patients with torn meniscus (equivalent to completely healthy synovial tissue) without a history of gout are used as a control, single-cell transcriptome analysis is carried out based on clinical biological samples, it is found that the marker TRBC2 of T cell subpopulation presents significant difference in gout patients, further Raman spectrum technology is used to find that TRBC2 protein is specifically highly expressed in synovial tissue of gouty arthritis patients, and has high diagnostic efficiency. The clinical value of TRBC2 as a marker for diagnosing gout is high, and the application prospect is wide.

To provide a method for restoring the synovial surface properties of a synovial surface film that has been damaged and whose synovial surface properties have deteriorated. [Solution] A method for restoring the synovial surface properties of a synovial surface film, comprising a standing step of allowing the damaged synovial surface film, whose synovial surface properties have deteriorated, to stand for more than 5 minutes, wherein the synovial surface film is a synovial surface film containing a liquid organic compound at 25°C and 1 atm.

Provided is a highly safe articular cartilage regeneration material. This articular cartilage regeneration material contains: a scaffold-free artificial tissue in which synovial-derived mesenchymal stem cells cultured with a serum-free medium form a three-dimensional structure; and an extracellular matrix derived from mesenchymal stem cells. The articular cartilage regeneration material is implanted so as to be attached to a site of lost or damaged articular cartilage.

The invention provides a detection reagent for LXOL2 gene expression quantity and application of LXOL2 as a rheumatoid arthritis treatment target, and relates to the technical field of biological medicines. According to an extracted total RNA sequence, a specific PCR primer is designed and synthesized, an RT-qPCR technology and a sequencing method are utilized, the expression of the LXOL2 in human synovial fibroblast-like cells is found to be remarkably increased, it is proved that the LXOL2 can be applied to preparation of a preparation for auxiliary diagnosis, treatment or prognosis evaluation of rheumatoid arthritis, meanwhile, Si-LOXL2 small in interference with the gene is designed and synthesized, and the application prospect is wide. According to the present invention, the expression of the LXOL2 gene can be knocked down, the expression of pro-inflammatory factors TNF-alpha, IL-1beta and IL-6 can be significantly inhibited, the expression of anti-inflammatory factors TGF-beta can be promoted, and the gene can be used as the RA molecular targeting treatment tool;

This invention relates to the field of pharmaceutical formulation and preparation and application technology, and particularly to a biomimetic carrier-free nanoparticle with synergistic effects of copper death and chemokinetics, its preparation method, and its application. The nanoparticle is constructed with a metallophenol network formed by the coordination self-assembly of gallic acid and copper ions, and coated with a neutrophil membrane. Copper ions can catalyze the generation of hydroxyl radicals from hydrogen peroxide through a Fenton-like reaction, inducing copper death in diseased synovial cells, thereby efficiently clearing inflammatory cells. Gallic acid exerts anti-inflammatory and antioxidant effects, synergistically regulating the inflammatory microenvironment. The neutrophil membrane endows the nanoparticle with the ability to actively target inflamed joints, effectively reducing off-target toxicity. The nanoparticles provided by this invention have advantages such as strong targeting, high biocompatibility, simple preparation, and a clear synergistic therapeutic mechanism, which can significantly improve the therapeutic effect of rheumatoid arthritis and reduce systemic toxic side effects.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a soluble epoxide hydrolase inhibitor, a pharmaceutical composition, a pharmaceutical preparation and application of the soluble epoxide hydrolase inhibitor in rheumatoid arthritis drugs. The invention provides a soluble epoxide hydrolase inhibitor which is a compound shown in a formula (I) or a tautomer, a stereoisomer, a hydrate, a solvate, a crystal form, a pharmaceutically acceptable salt or a prodrug thereof, and substituent groups R1-R23 are defined in the text. The soluble epoxide hydrolase inhibitor provided by the invention can remarkably inhibit proliferation, migration and invasion of fibroblast-like synovial cells, promote apoptosis of the fibroblast-like synovial cells and relieve the symptoms of rheumatoid arthritis, has relatively low side effects, and can prolong the half-life period of a drug in vivo.

The application discloses application of a benzyl piperidine compound in preparation of a medicine for treating gout, and finds that 25 mg / kg / day of the benzyl piperidine compound can significantly reduce ankle joint swelling degree and synovial hyperplasia of a gout rat through construction of a sodium urate-induced gout rat model and a sodium urate-induced fibroblast-like synoviocyte model, 1.8 muM of the benzyl piperidine compound can significantly inhibit activity of human primary fibroblast-like synoviocytes induced by sodium urate, and 3.6 muM of the benzyl piperidine compound can significantly inhibit invasion and migration ability of rat primary fibroblast-like synoviocytes induced by sodium urate. It is proved through in-vivo and in-vitro pharmacological experiments that the benzyl piperidine compound has a good effect of treating gout, can be used for preventing and treating gout diseases, and has a larger clinical application value.

The invention discloses an application of green tendon relaxing ketone in preparation of a medicine for treating rheumatoid diseases. The invention proposes and verifies that the green tendon relaxing ketone can effectively promote fibroblast-like synovial cell ferroptosis so as to inhibit synovial hyperplasia and inhibit the expression of proinflammatory cytokines so as to effectively relieve the progress of rheumatoid arthritis for the first time, and has an excellent application prospect in clinical treatment of rheumatoid diseases.

Techniques for implantable orthopedic pain management devices are disclosed, including incising an opening in a synovial capsule substantially surrounding a joint, using a first tool to form an enlarged opening in the synovial capsule, determining whether to modify the joint, the joint being modified using a second tool if a bone structure coupled to one or more bones is found within the joint and the bone structure is configured to limit articulation of the one or more bones when an implantable device is inserted into the synovial capsule and the joint, and inserting the implantable device into the synovial capsule through the enlarged opening, the implantable device being inserted into the joint using a third tool.